Nilotinib-Associated Destructive Thyroiditis

Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several si...

Full description

Saved in:
Bibliographic Details
Main Authors: Suhalia Bakerywala, Monica D. Schwarcz, Michael D. Goldberg, Guy Valiquette, Irene A. Weiss
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Case Reports in Endocrinology
Online Access:http://dx.doi.org/10.1155/2015/736092
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850233018876166144
author Suhalia Bakerywala
Monica D. Schwarcz
Michael D. Goldberg
Guy Valiquette
Irene A. Weiss
author_facet Suhalia Bakerywala
Monica D. Schwarcz
Michael D. Goldberg
Guy Valiquette
Irene A. Weiss
author_sort Suhalia Bakerywala
collection DOAJ
description Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several signaling pathways influencing cellular growth. Below we describe a patient who developed an unusual complication of tyrosine kinase inhibitor therapy: thyrotoxicosis due to destructive thyroiditis. We review the pathophysiology of tyrosine kinase inhibitor-induced thyroid dysfunction particularly with regard to new second-generation tyrosine kinase inhibitors.
format Article
id doaj-art-0d759ccd81ff4cd9aaf21ae48214498a
institution OA Journals
issn 2090-6501
2090-651X
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Case Reports in Endocrinology
spelling doaj-art-0d759ccd81ff4cd9aaf21ae48214498a2025-08-20T02:03:00ZengWileyCase Reports in Endocrinology2090-65012090-651X2015-01-01201510.1155/2015/736092736092Nilotinib-Associated Destructive ThyroiditisSuhalia Bakerywala0Monica D. Schwarcz1Michael D. Goldberg2Guy Valiquette3Irene A. Weiss4Division of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USADivision of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USADivision of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USADivision of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USADivision of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USAProtein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several signaling pathways influencing cellular growth. Below we describe a patient who developed an unusual complication of tyrosine kinase inhibitor therapy: thyrotoxicosis due to destructive thyroiditis. We review the pathophysiology of tyrosine kinase inhibitor-induced thyroid dysfunction particularly with regard to new second-generation tyrosine kinase inhibitors.http://dx.doi.org/10.1155/2015/736092
spellingShingle Suhalia Bakerywala
Monica D. Schwarcz
Michael D. Goldberg
Guy Valiquette
Irene A. Weiss
Nilotinib-Associated Destructive Thyroiditis
Case Reports in Endocrinology
title Nilotinib-Associated Destructive Thyroiditis
title_full Nilotinib-Associated Destructive Thyroiditis
title_fullStr Nilotinib-Associated Destructive Thyroiditis
title_full_unstemmed Nilotinib-Associated Destructive Thyroiditis
title_short Nilotinib-Associated Destructive Thyroiditis
title_sort nilotinib associated destructive thyroiditis
url http://dx.doi.org/10.1155/2015/736092
work_keys_str_mv AT suhaliabakerywala nilotinibassociateddestructivethyroiditis
AT monicadschwarcz nilotinibassociateddestructivethyroiditis
AT michaeldgoldberg nilotinibassociateddestructivethyroiditis
AT guyvaliquette nilotinibassociateddestructivethyroiditis
AT ireneaweiss nilotinibassociateddestructivethyroiditis